Drug Origin Transparency Act of 2026
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
The Drug Origin Transparency Act of 2026 aims to improve how information about drug manufacturing quantities is reported. This bill, introduced by Doris Matsui and co-sponsored by Dan Crenshaw, Kim Schrier, and Ashley Hinson, seeks to make sure that more detailed and accurate data about drug production is available to the public and regulatory bodies. This could help ensure better oversight and potentially safer medication practices.
This bill would primarily affect pharmaceutical companies, regulatory agencies, and consumers by requiring more transparency in drug production reporting. Companies would need to provide more detailed information about the amounts of drugs they manufacture, which could help in monitoring drug supply and addressing shortages. Consumers may benefit from better quality control and safety measures as a result.
As of April 16, 2026, HB8339 has just been introduced in the House and referred to the House Committee on Energy and Commerce. This is the first step in the legislative process, and further actions will depend on the committee's review and recommendations. The bill is still in its early stages, and more developments will follow as the committee examines and possibly amends the proposal.
